anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
During June, 2015, approximately 1200 women will be recruited through Facebook advertisements targeted at English-speaking women age 18-50 years living in the United States. Advertisements will contain 3 key features: an image, a caption, and "ad copy" followed by a link to the survey website. Individuals who click on the study link in the advertisement will be redirected to the study's Qualtrics web page where they will take a 15 web-page, multiple choice survey developed by the research team. The survey covers these domains: reaction to video, understanding of core message, self-efficacy around lifestyle behaviors, attitudes, beliefs and intentions regarding vaccination during pregnancy, key health information sources during pregnancy, and demographics.
The study will consist of a 4-week lead-in period to obtain a stable baseline measurement of clinical markers of disease and oxidative stress. After the lead-in phase, participants will receive trimetazidine for 12 weeks. Participants will visit the clinic at 6-week intervals, during which we will obtain a blood sample to measure the pharmacodynamic response. We will also collect information regarding the rate of disease progression (i.e. ALSFRS-R and SVC). At weeks 3 and 9 of treatment, participants will conduct a teleconference visit, during which we will collect data on ALSFRS-R. Adverse events will be collected and recorded throughout the entire trial duration. At the end of the on-treatment period, a close-out visit will occur after four weeks. The total study period per participant will be 20 weeks.
Dorsal penile nerve block plus ring block with 0.25% bupivacaine. Circumcision will be done using plastibell.
There is no known antidote for overdoses of epirubicin hydrochloride. A 36 year old man with non-Hodgkin’s lymphoma received a daily 95 mg/m2 dose of epirubicin hydrochloride injection for 5 consecutive days. Five days later, he developed bone marrow aplasia, grade 4 mucositis, and gastrointestinal bleeding. No signs of acute cardiac toxicity were observed. He was treated with antibiotics, colony-stimulating factors, and antifungal agents, and recovered completely. A 63 year old woman with breast cancer and liver metastasis received a single 320 mg/m2 dose of epirubicin hydrochloride. She was hospitalized with hyperthermia and developed multiple organ failure (respiratory and renal), with lactic acidosis, increased lactate dehydrogenase, and anuria. Death occurred within 24 hours after administration of epirubicin hydrochloride. Additional instances of administration of doses higher than recommended have been reported at doses ranging from 150 to 250 mg/m2. The observed adverse events in these patients were qualitatively similar to known toxicities of epirubicin. Most of the patients recovered with appropriate supportive care.

If an overdose occurs, provide supportive treatment (including antibiotic therapy, blood and platelet transfusions, colony-stimulating factors, and intensive care as needed) until the recovery of toxicities. Delayed CHF has been observed months after anthracycline administration. Observe patients carefully over time for signs of CHF and provide with appropriate supportive therapy.
The study includes 2 Parts and will be conducted at a single center. Part 1 is a randomized (study drug assigned by chance), double-blind (neither the volunteer or investigator knows the name of the assigned study drug), placebo-controlled (placebo is a substance that looks the same as JNJ-38431055 but contains no JNJ-38431055), single ascending dose study. In Part 1, study drug (i.e., JNJ-38431055 or placebo) will be administered orally as single doses on Day 1 or three treatment periods. In Part 1, for each volunteer, the study will consist of a screening evaluation visit, 3 periods of double-blind treatment, and a final, follow-up examination. The total study duration for each volunteer will be approximately 9 weeks. Part 2 is a randomized, open-label, 2-period crossover study to evaluate the effect of administering JNJ-38431055 together with food on the pharmacokinetics of JNJ-38431055, as compared to administration in the fasting condition. In Part 2, study drug (JNJ-38431055 will be administered orally as single doses on Day 1 or two treatment periods. There will be at least 7 days between doses. In Part 1, study drug (i.e., JNJ-38431055 or placebo) will be administered orally as single doses on Day 1 of three treatment periods. In Part 2, study drug (JNJ-38431055) will be administered orally as single doses on Day 1 of two treatment periods.
1359492 Medicated shampoo UNILEVER Ltd 28 April 1972 [28 Jan 1971] 3430/71 Heading C5D A germicidal shampoo includes opaque capsules containing 1-hydroxy-2-pyridine-thione or a salt thereof. The capsules may be wax capsules ot microcapsules permanently suspended in the shampoo. They may contain an aqueous dispersion of the sodium or zinc salt of 1-hydroxy-2-pyridinethione. Where the capsules contain 1 - hydroxy - 2 - pyridinethione itself or a water-soluble salt, the shampoo must contain a heavy metal salt, e.g. zinc sulphate. The shampoo may be clear or pearlescent. It may be packed in a transparent container. Other ingredients specified include sodium lauryl ether sulphate, lauric isopropanolamide, sodium chloride, montmorillonite clay, perfume and water.
OBJECTIVE: To explore the mediating effect of fatigue between social support and depression in hospitalized patients with ischemic stroke, so as to provide reference for improving post-stroke depression.
METHODS: A total of 142 hospitalized patients with ischemic stroke were enrolled and investigation was conducted with self-rating depression scale (SDS), social support rating scale (SSRS), and fatigue severity scale (FSS). Spearman's correlation analysis was used to analyze the correlation between the variables. A model for the mediating effect between the variables was established by using the AMOS 23.0 software to analyze the mediating effect of fatigue between social support and depression. The Bootstrap method was used to test the significance of intermediary effect.
RESULTS: The scores for SDS, SSRS, and FSS in the hospitalized ischemic stroke patients enrolled were 48.96±9.09, 31.34±8.35, and 30.70±13.99, respectively. Spearman's correlation analysis showed that depression was positively correlated with fatigue and negatively correlated with social support. In addition, fatigue was negatively correlated with social support. Analysis of the mediating effect model established that fatigue played a mediating role between social support and depression in patients with ischemic stroke, with the mediating effect value being -0.170 and the mediating effect accounting for 90.0% of the total effect.
CONCLUSION: The effect of social support on depression in hospitalized patients with ischemic stroke is mainly achieved by affecting the sense of fatigue. Health workers should pay attention to the severity of fatigue of patients and reduce their sense of fatigue as much as possible, which will help enhance social support for the patients and reduce their depression.
PURPOSE: Our aim was to investigate the course of the hearing capacity of the better-hearing ear in single-sided deafness (SSD) and asymmetric hearing loss (AHL) over time, in a multicenter study.
METHODS: We included 2086 pure-tone audiograms from 323 patients with SSD and AHL from four hospitals and 156 private practice otorhinolaryngologists. We collected: age, gender, etiology, duration of deafness, treatment with CI, number and monosyllabic speech recognition, numerical rating scale (NRS) of tinnitus intensity, and the tinnitus questionnaire according to Goebel and Hiller. We compared the pure tone audiogram of the better-hearing ear in patients with SSD with age- and gender-controlled hearing thresholds from ISO 7029:2017.
RESULTS: First, individuals with SSD showed a significantly higher hearing threshold from 0.125 to 8 kHz in the better-hearing ear compared to the ISO 7029:2017. The duration of deafness of the poorer-hearing ear showed no relationship with the hearing threshold of the better-hearing ear. The hearing threshold was significantly higher in typically bilaterally presenting etiologies (chronic otitis media, otosclerosis, and congenital hearing loss), except for Menière's disease. Second, subjects that developed AHL did so in 5.19 ± 5.91 years and showed significant reduction in monosyllabic word and number recognition.
CONCLUSIONS: Individuals with SSD show significantly poorer hearing in the better-hearing ear than individuals with NH from the ISO 7029:2017. In clinical practice, we should, therefore, inform our SSD patients that their disease is accompanied by a reduced hearing capacity on the contralateral side, especially in certain etiologies.
Study patients include nonsmokers aged 18-75 undergoing open abdominal wall surgery under general anesthesia. If the patient smokes, receives a regional anesthetic such as an epidural, or is pregnant, then he/she is excluded from the study. There are two randomized study groups. Group B receives a seven-milligram transdermal patch and Group A receives a placebo patch. Generic seven-milligram nicotine patches or identical placebo patches made from band-aids are glued to a 3x4 inch adhesive pad and placed on the individuals' right upper arm 1 hour before surgery. All patients are given a standardized anesthetic consisting of a narcotic infusion, propofol, a neuromuscular blocking agent, anesthetic gas agent, antinauseant medication and a nonsteroidal.

Patients receive postoperative analgesia for twenty four hours after surgery with a narcotic or an additional nonsteroidal medication. All patients receive intravenous controlled patient controlled analgesia (IVPCA) with morphine sulfate one milligram per ten minutes, forty milligram four hour limit. Patients also receive toradol fifteen milligrams for breakthrough pain. The patch is removed from participants twenty four hours post IVPCA initiation. The following items are assessed every four hours for twenty four hours after post anesthesia care unit discharge: a verbal rating of pain, total IVPCA morphine use, nausea occurrence, vomiting occurrence, and sedation score by the nurse.
The invention relates to application of totarol for production of a preparation for treatment of vaginal mucous membrane inflammations of bacterial origin, for alleviation of symptoms in such a treatment, and for prophylaxis and prevention of relapses of such inflammations. The invention includes also a pharmaceutical composition for treatment of vaginal mucous membrane inflammations of bacterial origin, for alleviation of symptoms in such a treatment and for prophylaxis and prevention of relapses of such inflammations, the composition containing from 75 to 95 parts by wt. of a cellulose derivative, from 0.5 to 5 parts by wt. of lactic acid, from 0.5 to 5 parts by wt. of a basic polymer, wherein the stoichiometric ratio of lactic acid to the basic polymer is comprised in the range of 1:1 to 8:1, and comprising totarol in an amount of 0.001 to 5 parts by wt. as the active substance.
<P>PROBLEM TO BE SOLVED: To obtain a bone metabolism modulation composition containing proanthocyanidin.  <P>SOLUTION: The bone metabolism modulation composition contains proanthocyanidin. Proanthocyanidin in the bone metabolism modulation composition is contained in a natural product-derived extract. Preferably the extract contains ≥20 wt.%, calculated as dry weight, of oligomeric proanthocyanidins of dimer-tetramer. Bone formation is promoted and balance of bone metabolism is restored to a healthy state by taking the bone metabolism modulation composition containing proanthocyanidin. The composition is useful in a health food or a medicine for preventing or ameliorating osteoporosis, or the like.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
PURPOSE:A make-up cosmetic, capable of changing the color tone reversibly by light stimulation without staining the skin or nail, and comprising a spiropyran compound in the form of a solid solution as a nucle substance enclosed in a microcapsule. CONSTITUTION:A spiropyran compound is dispersed in an oil-soluble resin, e.g. polyacrylic acid, to give a solid solution, which is then pulverized and as a nuclear substance enclosed in a wall membrane to form a microcapsule. The formation of the microcapsule is preferably carried out by the coacervation with a polycation or polyanion as the wall membrane material. 0.1-20wt% the microcapsule is then mixed with a cosmetic oil or foundation to give a cosmetic capable of changing the color tone reversibly in the room and outdoors. The cosmetic is characterized by the prevented fatigue phenomenon by light stimulation which is a disadvantage of the spiropyran compound.
Impressions of the upper arch will be taken at the day of bracket debonding and the retainer will be delivered in 24 hours. TheraMon microchip will be embedded within the appliance and patients will be instructed to wear the appliance 24 hours/ day.
BACKGROUND: Gestational diabetes mellitus (GDM) is a prevalent pregnancy complication during pregnancy. We aimed to evaluate a risk prediction model of GDM based on traditional and genetic factors.
METHODS: A total of 2744 eligible pregnant women were included. Face-to-face questionnaire surveys were conducted to gather general data. Serum test results were collected from the laboratory information system. Independent risk factors for GDM were identified using univariate and multivariate logistic regression analyses. A GDM risk prediction model was constructed and evaluated with the Hosmer-Lemeshow goodness-of-fit test, goodness-of-fit calibration plot, receiver operating characteristic curve and area under the curve.
RESULTS: Among traditional factors, age ≥30 years, family history, GDM history, impaired glucose tolerance history, systolic blood pressure ≥116.22 mmHg, diastolic blood pressure ≥74.52 mmHg, fasting plasma glucose ≥5.0 mmol/L, 1-hour postprandial blood glucose ≥8.8 mmol/L, 2-h postprandial blood glucose ≥7.9 mmol/L, total cholesterol ≥4.50 mmol/L, low-density lipoprotein ≥2.09 mmol/L and insulin ≥11.5 mIU/L were independent risk factors for GDM. Among genetic factors, 11 single nucleotide polymorphisms (SNPs) (rs2779116, rs5215, rs11605924, rs7072268, rs7172432, rs10811661, rs2191349, rs10830963, rs174550, rs13266634 and rs11071657) were identified as potential predictors of the risk of postpartum DM among women with GDM history, collectively accounting for 3.6% of the genetic risk.
CONCLUSIONS: Both genetic and traditional factors contribute to the risk of GDM in women, operating through diverse mechanisms. Strengthening the risk prediction of SNPs for postpartum DM among women with GDM history is crucial for maternal and child health protection.
The risks of using SEROQUEL XR in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of SEROQUEL XR, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of alcohol in a clinical trial in subjects with selected psychotic disorders, and alcoholic beverages should be limited while taking quetiapine. 

Because of its potential for inducing hypotension, SEROQUEL XR may enhance the effects of certain antihypertensive agents. 

SEROQUEL XR may antagonize the effects of levodopa and dopamine agonists.

The use of quetiapine should be avoided in combination with drugs known to increase QT interval, and caution should be exercised when quetiapine is used in combination with drugs known to cause electrolyte imbalance [see Warnings and Precautions (5.12)].

There have been literature reports suggesting false positive results in urine enzyme immunoassays for methadone and tricyclic antidepressants in patients who have taken quetiapine. Caution should be exercised in the interpretation of positive urine drug screen results for these drugs, and confirmation by alternative analytical technique (e.g. chromatographic methods) should be considered.
If hepatic and renal functions become impaired and elimination of the drug decreases accumulation may occur. Discontinuation of Thermazene Cream should be weighed against the therapeutic benefit being achieved.

In considering the use of topical proteolytic enzymes in conjunction with Thermazene Cream, the possibility should be noted that silver may inactivate such enzymes.

In the treatment of burn wounds involving extensive areas of the body, the serum sulfa concentrations may approach adult therapeutic levels (8 to 12mg %). Therefore, in these patients it would be advisable to monitor serum sulfa concentrations. Renal function should be carefully monitored and the urine should be checked for sulfa crystals.   


Absorption of the propylene glycol vehicle has been reported to affect serum osmolality, which may affect the interpretation of laboratory tests.
FIELD: veterinary science and medicine. SUBSTANCE: invention relates to development of disinfectant agent - "Theotropin" of the formula (C 18 H 16 N 4 ). Preparation shows virulicide and Bactericidal effect, low toxicity level and chemical aggressivity. Disinfection is carried out with 0.1-5% aqueous solutions of preparation by methods of spraying or as an aerosol. Preparation does not exhibit toxic effect on animals and birds. It can be synthesized from the home raw and retains its disinfecting properties in aqueous solution for 120 days, not less. Preparation is used for disinfection of equipment, tools, devices and so on from pathogenic viruses. EFFECT: enhanced effectiveness of preparation. 4 tbl
The invention relates to taurine modified graphene oxide drug-loaded 5-fluorouracil and a preparation method and application thereof. Slowly dropwise adding a taurine solution after ultrasonically activating a graphene oxide solution, adjusting the pH value, centrifuging, washing and drying to obtain TCA-GO, dissolving the TCA-GO in water, ultrasonically stripping, adding a 5-fluorouracil aqueous solution, and adjusting the pH value. After the reaction under stirring in the shade, the unsupported 5-FU is removed by centrifugation and freeze-dried to form a TCA-GO/5-FU complex. The carrier material of the invention has excellent solubility in water and stronger stability, and the particle size meets the standard of a nano drug-carrying system. Meanwhile, the system has the function of sustained and controlled release, prolongs the detention time of the 5-FU in vivo and enhances the curative effect. The invention can be applied to anti-tumor research and has good clinical research and application values.
The disclosure provides for an apparatus for intraocular lens selection. The apparatus may include a biometer and an autorefractor. The biometer may be configured to obtain at least two ocular measurement parameters for an eye. The autorefractor may be configured to obtain a post-operative refraction of the eye. The apparatus may also include a user interface configured to obtain a lens selection parameter for the eye, a memory, and a processor communicatively coupled to the biometer, the user interface, the autorefractor, and the memory. The processor may be configured to determine an intraocular lens power based on a formula using the at least two ocular measurement parameters. The processor may be configured to correlate the at least two ocular measurement parameters, the intraocular lens power, and the post-operative refraction as a training set.
A method is provided for clustering data elements to extract specific patterns. The method specifies some data elements with a uniform distribution as a mini-batch and performs a single-pass cluster initialization by selecting a respective data element from the mini-batch as a respective initial cluster center to obtain cluster centers for clusters. The method assigns each data element in the mini-batch to a closest cluster by calculating a distance between each of the data elements in the mini-batch and each of the clusters. The method assigns k-minimum new centers by calculating an averaged distance to each data element in a same cluster. The method repeats the specifying step and the assigning steps responsive to a dissatisfaction of loop stop criteria which is based on distances between the centers and the K-minimum new centers. The method outputs a cluster id sequence responsive to a satisfaction of the loop stop criteria.
The intervention will be 12 weeks in duration and will consist of a series of pre-approved online yoga classes. MPN patients will be asked to complete a minimum of 60 minutes per week of yoga practice with encouragement to do more if they can. All Udaya.com videos will include a proper warm-up, cool down, and closing mindfulness activity (i.e., message from yoga therapist, brief meditation, final relaxation). Qualified Udaya yoga instructors who collectively have over 200 years of training and experience will expertly instruct the online yoga classes.
This is an observational longitudinal study to assess incidence of SARS-CoV-2 infection in Brazil. The study sample is stratified in nine age groups according decades of life, equally distributed in both sexes, with an expected incidence of 10%, at least, during the study period of 24 months. For the first age groups, (0-9, 10-19 and 20-29 years), sample was calculated with the minimum expected incidence of COVID-19 among infected, regardless severity, is 10%. For the latest age groups (30-39, 40-49, 50-59, 60-69, 70-79 and 80+), the sample was calculated with the expected minimum incidence of hospitalization due to COVID-19 according to estimates per age group reported by Verity R et al. https://doi.org/10.1016/S1473-3099(20)30243-7 After the consent procedure, all participants will have a short interview, a IgG/IgM SARS-CoV-2 rapid test and a blood withdrawal to obtain serum for neutralizing antibodies. These procedures will be repeated every four weeks until the end of the study. Individuals with symptoms compatible will be followed-up to confirm COVID-19 diagnosis as well as to assess severity, need for hospitalization and assisted ventilation, sequels, and eventual reinfection. Levels of neutralizing antibodies and other immune markers will be prospectively assessed in all infected participants, either asymptomatic and symptomatic.
Non-valvular atrial fibrillation (NVAF) is the most common sustained arrhythmia worldwide, and is associated with significant morbidity and mortality. Increasing life expectancy, coupled with a surge in comorbidity burden, has resulted in a sharp increase in NVAF prevalence over the last three decades. Coronary artery disease (CAD) is an important and clinically relevant risk factor of AF. Concomitant CAD has significant implications for AF management and is a major determinant of the overall outcomes. Shared risk factors, a common pathophysiological basis, and heightened thrombogenesis culminating in cardiovascular adverse events, highlight the close association between the two. The clinical course of AF is worse when associated with CAD, resulting in poor heart rate control, increased propensity to develop stroke and myocardial infarction, increased likelihood of acute presentation with hemodynamic collapse and pulmonary edema, increased bleeding tendencies, and poor response to ablation therapies. Emerging research highlighting the significant role of underlying CAD as an independent predictor of thromboembolic risk has paved the way for the adoption of CAD beyond prior myocardial infarction into the symbol "V" of the CHA2DS2-VASc score. In our opinion, elderly patients aged >65 years with AF, with a history of one or more cardiovascular comorbidities, or evidence of atherosclerosis in other vascular beds should warrant a closer look and a dedicated effort to look for associated CAD. This would allow for a more holistic and comprehensive approach to patients with AF and ultimately help reduce the disease burden and improve the overall outcomes.